XRCC1 and lung cancer: As shown in Fig. 4, our cumulative meta-analyses based on year of publication indicated that there was a distinct trend toward a better response rate to platinum-based chemotherapy treatment with advanced lung cancer patients for the XRCC1 Arg194Trp polymorphism (TrpTrp+TrpArg vs. ArgArg, Fig. 4).